Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

被引：61

作者：

Weiner, Michael W. ^{[1
,2
,3
,4
,5
]}

Veitch, Dallas P. ^{[1
,6
]}

Miller, Melanie J. ^{[1
,6
]}

Aisen, Paul S. ^{[7
]}

Albala, Bruce ^{[8
]}

Beckett, Laurel A. ^{[9
]}

Green, Robert C. ^{[10
,11
]}

Harvey, Danielle ^{[9
]}

Jack, Clifford R., Jr. ^{[12
]}

Jagust, William ^{[13
]}

Landau, Susan M. ^{[13
]}

Morris, John C. ^{[14
,15
,16
]}

Nosheny, Rachel ^{[1
,4
]}

Okonkwo, Ozioma C. ^{[17
,18
]}

Perrin, Richard J. ^{[14
,15
,16
]}

Petersen, Ronald C. ^{[19
]}

Rivera-Mindt, Monica ^{[20
,21
,22
]}

Saykin, Andrew J. ^{[23
,24
,25
]}

Shaw, Leslie M. ^{[26
,27
]}

Toga, Arthur W. ^{[28
]}

Tosun, Duygu ^{[1
,2
]}

Trojanowski, John Q. ^{[26
,27
]}

机构：

[1] Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA USA

[2] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

[3] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[4] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA 94143 USA

[5] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[6] Northern Calif Inst Res & Educ NCIRE, Dept Vet Affairs Med Ctr, San Francisco, CA USA

[7] Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego, CA USA

[8] Univ Calif Irvine, Dept Neurol, Sch Med, Irvine, CA 92717 USA

[9] Univ Calif Davis, Div Biostat, Dept Publ Hlth Sci, Davis, CA 95616 USA

[10] Brigham & Womens Hosp, Dept Med, Div Genet, Broad Inst Ariadne Labs, 75 Francis St, Boston, MA 02115 USA

[11] Harvard Med Sch, Boston, MA 02115 USA

[12] Mayo Clin, Dept Radiol, Rochester, MN USA

[13] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA

[14] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, St Louis, MO USA

[15] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA

[16] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA

[17] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA

[18] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA

[19] Mayo Clin, Dept Neurol, Rochester, MN USA

[20] Fordham Univ, Dept Psychol, Latin Amer & Latino Studies Inst, New York, NY 10023 USA

[21] Fordham Univ, African & African Amer Studies, New York, NY 10023 USA

[22] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA

[23] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA

[24] Indiana Univ Sch Med, Indiana Alzheimers Dis Res Ctr, Indianapolis, IN 46202 USA

[25] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA

[26] Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Res, Perelman Sch Med, Philadelphia, PA USA

[27] Univ Penn, PENN Alzheimers Dis Res Ctr, Ctr Neurodegenerat Res, Perelman Sch Med, Philadelphia, PA 19104 USA

[28] Univ Southern Calif, Keck Sch Med, Lab Neuro Imaging, Inst Neuroimaging & Informat, Los Angeles, CA 90007 USA

来源：

ALZHEIMERS & DEMENTIA | 2023年 / 19卷 / 01期

关键词：

Alzheimer's disease; amyloid; cerebrovascular disease; digital biomarkers; generalizability; mild cognitive impairment; plasma biomarkers; tau; underrepresented populations; VALIDATION; BIOMARKER; DEMENTIA;

D O I：

10.1002/alz.12797

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (similar to 3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and Discussion ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.

引用

页码：307 / 317

页数：11

共 2 条

[1] The Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core: A culturally informed, community-engaged research (CI-CER) model to advance brain health equity
Mindt, Monica Rivera
Arentoft, Alyssa
Calcetas, Amanda T.
Guzman, Vanessa A.
Amaza, Hannatu
Ajayi, Adeyinka
Ashford, Miriam T.
Ayo, Omobolanle
Barnes, Lisa L.
Camuy, Alicia
Conti, Catherine
Diaz, Adam
Easter, Bashir
Gonzalez, David J.
Dotson, Yolanda Graham
Hoang, Isabella
Germano, Kaori Kubo
Maestre, Gladys E.
Magana, Fabiola
Meyer, Oanh L.
Miller, Melanie J.
Nosheny, Rachel
Park, Van M. Ta
Parkins, Shaniya
Thomas, Lisa Renier
Strong, Joe
Talavera, Sandra
Verney, Steven P.
Weisensel, Trinity
Weiner, Michael W.
Okonkwo, Ozioma C.
ALZHEIMERS & DEMENTIA, 2024, 20 (12) : 8279 - 8293
[2] A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research
O'Bryant, Sid E.
Zhang, Fan
Petersen, Melissa
Hall, James R.
Johnson, Leigh A.
Yaffe, Kristine
Mason, David
Braskie, Meredith
Barber, Robert A.
Rissman, Robert A.
Mapstone, Mark
Mielke, Michelle M.
Toga, Arthur W.
ALZHEIMERS & DEMENTIA, 2022, 18 (01) : 77 - 87

← 1 →